Insmed discovered Brensocatib for the treatment of adult patients with Non-cystic Fibrosis Bronchiectasis (NCFBE) for reducing exacerbations.
Brensocatib is a novel oral, reversible inhibitor of Dipeptidyl Peptidase 1 (DPP1) for the treatment of bronchiectasis and other inflammatory diseases. DPP1 an enzyme capable for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils formed in the bone marrow. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.
Non-cystic Fibrosis Bronchiectasis (NCFBE)is a seriousand life threatening, chronic pulmonary disorderin which bronchi enlarges permanentlydue to a cycle of infection, inflammation and damage lung tissues.Some of the symptoms are excessive sputum production, shortness of breath, and repeated respiratory infections worsening the underlying condition and chronic cough.
Approximately 340,000 to 520,000 people in the U.S are affected with NCFBE. Unfortunately, there are currently no approved therapies for treating these disorders in the United States, Europe, or Japan. Brensocatib a novel, first-in-class treatment was approved for bronchiectasis.
Brensocatib was approved breakthrough designation based on the positive results from the global randomized, double-blind, placebo-controlled Phase 2 WILLOW study of brensocatib in adults with NCFBE.
